Vol. 14/No. 4

Jerome D. Winegarden, MD, discusses the importance of recruiting international students to such programs.

In a full-circle scenario, Cedars-Sinai Cancer, based in Los Angeles, California, welcomed back Margaret Liang, MD, MSHPM, in July 2023 to the institution where she completed her fellowship.

Stephen T Magill, MD, PhD, details his inspirations behind entering not just the neuro-oncology and surgical treatment field, but also the arena of meningioma care and research; provides topline advice for current fellows looking to enter this field; and details current and ongoing research in this space taking place at Northwestern Medicine.

The risk for developing hepatocellular carcinoma appears to increase with subsequent generations for Americans of Mexican descent, according to findings from a study of US-born Hispanics/Latinos living in Los Angeles, California.

Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.

Similar to first-line therapy choices, particular treatment factors, including type and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.

Erin K. Crane, MD, MPH, talked to Oncology Fellows about helping trainees care for their own health and wellness, navigate the politics surrounding gynecologic care, and the lessons she hopes they take away from the program.

The Dobbs v Jackson Women’s Health Organization decision, a landmark decision of the US Supreme Court in which the court held that the Constitution of the United States does not confer a right to abortion, will most likely affect your practice.

As more and more people in the United States identify as lesbian, gay, bisexual, transgender, queer, intersex, or other sexual orientation or gender minority, the population of LGBTQI+ cancer survivors is becoming uniquely heterogeneous.

The Ivy Brain Tumor Center at Barrow Neurological Institute in Phoenix, Arizona, is attempting to change the way preclinical studies are developed and conducted to assess the efficacy of drugs for glioblastoma multiforme.